Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Baron

Showing results (51-60 of 198) with videos related to

Pageof 20
Sort By:
Frontiers in Bioscience (Scholar Edition)|January 3, 2018
Molecular role of dopamine in anhedonia linked to reward deficiency syndrome (RDS) and anti- reward systemsMark S Gold, Kenneth Blum, Marcelo Febo, et al.
Substance Use & Misuse|September 22, 2020
Putative COVID- 19 Induction of Reward Deficiency Syndrome (RDS) and Associated Behavioral Addictions with Potential Concomitant Dopamine Depletion: Is COVID-19 Social Distancing a Double Edged Sword?Kenneth Blum, Jean Lud Cadet, David Baron, et al.
Madridge Journal of Molecular Biology|September 22, 2023
Can We Combat Reward Deficiency Behaviors (RDS) including Substance Use Disorder (SUD) through Genetic Risk Screening coupled with Precision Pro-Dopamine Regulation by Algorithmic matched Polymorphic Allelic RisksKenneth Blum, David Baron, Mary Hauser, et al.
Gastroenterology|June 5, 2020
Emerging Phenotype of Severe Acute Respiratory Syndrome-Coronavirus 2-associated PancreatitisPeter Szatmary, Ankur Arora, Michael Godwin Thomas Raraty, et al.
Psychology Research and Behavior Management|December 14, 2023
Futuristic Exploration of Addiction Neuroscience in the Genomic EraKenneth Blum, Igor Elman, Abdalla Bowirrat, et al.
The Journal of Nervous and Mental Disease|January 3, 2020
Pharmacogenomic Testing in Psychiatry: Ready for Primetime?Gopalkumar Rakesh, Calvin R Sumner, Jeanne Leventhal Alexander, et al.
Journal of Systems and Integrative Neuroscience|October 28, 2021
Polygenic and multi locus heritability of alcoholism: Novel therapeutic targets to overcome psychological deficitsKenneth Blum, David Baron, Rehan Jalali, et al.
Current Trends in Medical Diagnostic Methods|July 6, 2019
Genetic Addiction Risk Score (GARS<sup>™</sup>) as a Predictor of Substance Use Disorder: Identifying Predisposition Not DiagnosisKenneth Blum, Lisa Lott, David Siwicki, et al.
Neurology (E-Cronicon)|June 4, 2021
Psychoactive Drugs Like Cannabis -Induce Hypodopaminergic Anhedonia and Neuropsychological Dysfunction in Humans: Putative Induction of Dopamine Homeostasis via Coupling of Genetic Addiction Risk Severity (GARS) testing and Precision Pro-dopamine Regulation (KB220)Kenneth Blum, Joseph Morgan, Jean Lud Cadet, et al.
Journal of Reward Deficiency Syndrome and Addiction Science|August 15, 2017
Pro-Dopamine Regulator - (KB220) to Balance Brain Reward Circuitry in Reward Deficiency Syndrome (RDS)Kenneth Blum, Marcelo Febo, Lyle Fried, et al.
Pageof 20

Showing results (51-60 of 198) with videos related to

Sort By:
Pageof 20
Frontiers in Bioscience (Scholar Edition)|January 3, 2018
Molecular role of dopamine in anhedonia linked to reward deficiency syndrome (RDS) and anti- reward systemsMark S Gold, Kenneth Blum, Marcelo Febo, et al.
Substance Use & Misuse|September 22, 2020
Putative COVID- 19 Induction of Reward Deficiency Syndrome (RDS) and Associated Behavioral Addictions with Potential Concomitant Dopamine Depletion: Is COVID-19 Social Distancing a Double Edged Sword?Kenneth Blum, Jean Lud Cadet, David Baron, et al.
Madridge Journal of Molecular Biology|September 22, 2023
Can We Combat Reward Deficiency Behaviors (RDS) including Substance Use Disorder (SUD) through Genetic Risk Screening coupled with Precision Pro-Dopamine Regulation by Algorithmic matched Polymorphic Allelic RisksKenneth Blum, David Baron, Mary Hauser, et al.
Gastroenterology|June 5, 2020
Emerging Phenotype of Severe Acute Respiratory Syndrome-Coronavirus 2-associated PancreatitisPeter Szatmary, Ankur Arora, Michael Godwin Thomas Raraty, et al.
Psychology Research and Behavior Management|December 14, 2023
Futuristic Exploration of Addiction Neuroscience in the Genomic EraKenneth Blum, Igor Elman, Abdalla Bowirrat, et al.
The Journal of Nervous and Mental Disease|January 3, 2020
Pharmacogenomic Testing in Psychiatry: Ready for Primetime?Gopalkumar Rakesh, Calvin R Sumner, Jeanne Leventhal Alexander, et al.
Journal of Systems and Integrative Neuroscience|October 28, 2021
Polygenic and multi locus heritability of alcoholism: Novel therapeutic targets to overcome psychological deficitsKenneth Blum, David Baron, Rehan Jalali, et al.
Current Trends in Medical Diagnostic Methods|July 6, 2019
Genetic Addiction Risk Score (GARS<sup>™</sup>) as a Predictor of Substance Use Disorder: Identifying Predisposition Not DiagnosisKenneth Blum, Lisa Lott, David Siwicki, et al.
Neurology (E-Cronicon)|June 4, 2021
Psychoactive Drugs Like Cannabis -Induce Hypodopaminergic Anhedonia and Neuropsychological Dysfunction in Humans: Putative Induction of Dopamine Homeostasis via Coupling of Genetic Addiction Risk Severity (GARS) testing and Precision Pro-dopamine Regulation (KB220)Kenneth Blum, Joseph Morgan, Jean Lud Cadet, et al.
Journal of Reward Deficiency Syndrome and Addiction Science|August 15, 2017
Pro-Dopamine Regulator - (KB220) to Balance Brain Reward Circuitry in Reward Deficiency Syndrome (RDS)Kenneth Blum, Marcelo Febo, Lyle Fried, et al.
Pageof 20